JP Patent

JP2013507395A — Ｃｎｓ障害治療用の８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン

Assigned to Afraxis Inc · Expires 2013-03-04 · 13y expired

What this patent protects

本発明は、PAK阻害剤およびPAK阻害剤をCNS障害、例えば精神神経障害、の治療に利用する方法を提供する。

USPTO Abstract

本発明は、PAK阻害剤およびPAK阻害剤をCNS障害、例えば精神神経障害、の治療に利用する方法を提供する。

Drugs covered by this patent

Patent Metadata

Patent number: JP2013507395A
Jurisdiction: JP
Classification: —
Expires: 2013-03-04
Drug substance claim: No
Drug product claim: No
Assignee: Afraxis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.